跳到正文
原文
Medical Xpress·· 2026-10-21精选AI 评分64

ADAPT-Sepsis 过程评估显示 PCT 指导较 CRP 提前近两天建议脓毒症患者停用抗生素

Daily blood tests flag potential to stop sepsis antibiotics nearly two days early

AI 导读

一项纳入英国 41 个 ICU、2,760 名患者的 ADAPT-Sepsis 过程评估显示,基于降钙素原(PCT)的每日血检提示比基于 C 反应蛋白(CRP)的提示提前近两天建议停用抗生素。医生更倾向采纳 CRP 生成的建议,但 PCT 更早的信号在减少抗生素总量上潜力更大。医生未采纳停药建议的最常见原因是微生物学指南规定的固定疗程,研究发表于 Anaesthesia。

推荐理由

ADAPT-Sepsis 过程评估对比 PCT 与 CRP 两种标志物的停药提示时机,并呈现医生未采纳建议的原因,可供抗菌药物管理参考。

正文
blood tests
Credit: Los Muertos Crew from Pexels

A simple daily blood test could help critically ill sepsis patients come off antibiotics sooner, potentially reducing drug overuse and helping tackle the growing threat of antibiotic resistance, new research shows. The study, led by researchers at the University of Manchester and Northern Care Alliance NHS Foundation Trust, involved 2,760 patients in 41 intensive care units across the U.K. and is published in the journal Anaesthesia.

The team found monitoring levels of a blood marker called procalcitonin (PCT) prompted doctors to consider stopping antibiotics significantly earlier than another commonly used marker, C-reactive protein (CRP).

The ADAPT-Sepsis trial examines how doctors respond to automated advice generated from daily blood tests designed to guide decisions on when antibiotic treatment could safely end.

The new data add to the evidence already gathered through the ADAPT-Sepsis research program. This process evaluation provides the final piece of the puzzle on whether the approach could be adopted across the NHS.

Sepsis is a life-threatening condition caused by the body's overwhelming response to infection and is responsible for thousands of deaths every year. Patients often receive prolonged courses of powerful antibiotics because doctors are understandably cautious about stopping treatment too soon in severely ill patients.

But unnecessary antibiotic use can fuel antimicrobial resistance, increase side effects and add to health care costs.

The researchers found that procalcitonin-based guidance generated "stop antibiotics" recommendations nearly two days earlier than guidance based on CRP—a significant reduction.

Though doctors were more likely to follow advice generated from CRP testing, the earlier signals produced by procalcitonin offer greater potential to cut the total amount of antibiotics patients receive. CRP testing more closely reflects existing prescribing habits and tends to recommend continuing standard care.

More than 17,000 blood samples and pieces of treatment advice were analyzed during the trial. The most common reason doctors chose not to follow recommendations to stop antibiotics was existing microbiology guidance recommending fixed treatment durations. Other reasons included concerns about ongoing severe illness, persistent fever and raised inflammation markers.

Principal researcher Paul Dark is vice dean for health and care partnerships at The University of Manchester and professor of critical care medicine at the Northern Care Alliance NHS Foundation Trust. He said, "For decades, intensive care doctors have faced an impossible balancing act. Nobody wants to stop antibiotics too early and risk a patient's life, but continuing them unnecessarily also carries real dangers for individuals and society.

"What our study shows is that simple biomarker tests can provide an additional layer of reassurance when making these difficult decisions. The challenge now is helping health care teams feel confident acting on that information so patients receive exactly the treatment they need, for exactly as long as they need it.

"Blood-test-guided antibiotic stewardship could become an important tool in the fight against antimicrobial resistance if implemented alongside existing clinical guidance and prescribing frameworks.

"These findings provide new insight into how hospitals could safely reduce antibiotic exposure in some of the sickest patients in the NHS while helping preserve the effectiveness of lifesaving drugs for future generations."

Rupert Pearse, chair of the NIHR-HTA commissioning committee, said, "Research like the ADAPT-Sepsis trial plays a key role in tackling the threat posed globally by antimicrobial resistance. The study team's results help to provide vital evidence for medical professionals, giving them a greater understanding of how best to treat sepsis patients and, crucially, identify when it is safe for antibiotic treatment to be halted."

Publication details

Ranjit Lall et al., Delivery and adherence of biomarker‐guided antibiotic treatment protocols in the ADAPT-Sepsis clinical trial: an in-trial descriptive process evaluation of daily procalcitonin- and C-reactive protein-guided protocols, Anaesthesia (2026). DOI: 10.1111/anae.70439

Journal information: Anaesthesia

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Daily blood tests flag potential to stop sepsis antibiotics nearly two days early (2026, October 21) retrieved 21 October 2026 from https://medicalxpress.com/news/2026-10-daily-blood-flag-potential-sepsis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com